Study Type
Interventional - Drug
The AXIOMATIC SSP study is a global, phase 2, randomized, double-blind, placebo-controlled, dose-ranging Study of BMS-987177, an oral factor XIa inhibitor, for the prevention of new ischemic stroke or new silent brain infraction in patients receiving aspirin and clopidogrel following acute non-hemorrhagic stroke or transient ischemia attack (TIA).
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to aspirin and clopidogrel is more effective than standard therapy in secondary stroke prevention.
More about this study at: ClinicalTrials.gov.
Interventional - Drug
Double-blind placebo-controlled dose-ranging RCT
28
380
2350
2019 - 2021
Bristol Myers Squibb, Janssen
Back To Top